Abstract 4385
Background
For cancer prevention and early diagnostics oncological awareness of the ordinary people is crucial. The knowledge of the problem is extremely important in young population. The aim of the study was to assess the basic oncological knowledge of high school students.
Methods
The study was conducted among high school students in Olsztyn in Poland between April 2017 and April 2018. It was a part of a health promotion program focused on oncological education for high school students in Warmia and Mazury District. The examination was carried out at the beginning of lectures conducted by medical students. The respondents filled in a questionnaire especially prepared for this study. Participation in the study was voluntary and anonymous. The chi-square test was used to compare the subgroups. A p-value <0.05 was considered significant. Statistical analysis was done using STATISTICA software 13.1 (Statsoft, Poland).
Results
The study was done on 227 students (age 17-18 years) from 5 high schools in Olsztyn. There were 125 female and 101 male (one unknown). Almost 80% of responders could correctly defined cancer disease. 153 students (67%) believed genetic predispositions to be the greatest factor affecting cancer morbidity. At the same time, 183 responders (81%) claimed that people have an impact on cancer development. But only 19% students indicated smoking as an important cancerogenous factor and none alcohol. Diet and physical activity influence on cancer prevalence were known only by 5 and 2 students, respectively. Over half of students (58%) thought they lead a healthy lifestyle, but almost 1/3 respondents smoke cigarettes. All students except eight (97%) believed that early detected cancer can be successfully treated. There was no difference depending on sex and place of residence in all questions.
Conclusions
The impact of genetic predispositions in neoplastic diseases seems to be overestimated by high school students. Students knew that lifestyle has an impact on cancer disease, but they did not associate smoking, alcohol, diet, physical activity with a healthy lifestyle. There is a need for more education about cancer and its’ prophylactic among high school students in Poland.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2421 - Lenvatinib plus PD-1 blockade in advanced bile tract carcinoma.
Presenter: Jianzhen Lin
Session: Poster Display session 3
Resources:
Abstract
5368 - Durvalumab and Paclitaxel Combination for treatment of metastatic triple negative breast cancer is safe with very promising efficacy
Presenter: Hazem Ghebeh
Session: Poster Display session 3
Resources:
Abstract
1520 - A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients
Presenter: Daan Hurkmans
Session: Poster Display session 3
Resources:
Abstract
1603 - Safety and clinical activity of subcutaneously (SC) administered anti-PD-1 antibody PF-06801591 in phase I dose-expansion cohorts of locally advanced or metastatic non-small-cell lung cancer (NSCLC) and urothelial carcinoma (UC)
Presenter: Byoung Cho
Session: Poster Display session 3
Resources:
Abstract
3922 - Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A scale to measure quality of life in cancer patients treated with ICMs
Presenter: Aaron Hansen
Session: Poster Display session 3
Resources:
Abstract
2408 - Immune checkpoint inhibitors (ICIs) as “chemotherapy (Ctx) sensitization” strategy in advanced solid tumors
Presenter: Francisco Javier Ros Montana
Session: Poster Display session 3
Resources:
Abstract
3612 - Validation of progression-free survival (PFS) as surrogate endpoint in randomised trials of immune checkpoint inhibitors in advanced solid cancers
Presenter: Peey Sei Kok
Session: Poster Display session 3
Resources:
Abstract
3827 - Pharmacokinetic (PK) analysis of weight-based and fixed dose cemiplimab in patients (pts) with advanced malignancies
Presenter: Michael Migden
Session: Poster Display session 3
Resources:
Abstract
2120 - A burst of highly differentiated CD4 TL identifies a subset of fast progressors, and correlates with hyperprogressive disease in NSCLC patients treated with ICI
Presenter: Hugo Arasanz
Session: Poster Display session 3
Resources:
Abstract
4254 - Nivolumab treatment in advanced non-small cell lung cancer (aNSCLC): a French nationwide retrospective cohort (UNIVOC Study)
Presenter: Christos Chouaid
Session: Poster Display session 3
Resources:
Abstract